Nanjing Leads rises on clinical study progress on cancer treatment drug
25/08/2026 06:43
BUZZ-Nanjing Leads rises on clinical study progress on cancer treatment drug ** Shares of Nanjing Leads Biolabs 9887.HK jump 9.2% to HK$75.4, their biggest intraday pct gain since July 15
** The China-based oncology and autoimmune therapies developer says Phase II clinical study of its drug candidate LBL-024 as a first-line treatment for patients with metastatic esophageal squamous cell carcinoma has completed the safety lead-in stage and has advanced to the combination treatment expansion stage
** LBL-024 has demonstrated a favourable safety and tolerability profile in about 800 patients treated to date, supporting its development as a potential next-generation immuno-oncology backbone therapy, says Nanjing Leads
** YTD, stock up 46.2%, Hang Seng Biotech Index .HSBIO up 11.5%
(Reporting by Donny Kwok)
Recent news on Nanjing Leads Biolabs
See all newsBrief: Nanjing Leads Biolabs Says FDA Grants Fast Track Designation To LBL-024
Brief: Nanjing Leads Biolabs Posts HY Loss Attributable RMB221.9 Million
Nanjing Leads rises on clinical study progress on cancer treatment drug
Nanjing Leads Biolabs jumps on progress of tumor antibody treatment
Nanjing Leads Biolabs rises on NMPA's IND approval for colorectal cancer